Ignite Creation Date:
2024-05-05 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00085904
Status:
COMPLETED
Last Update Posted:
2008-10-13
First Post:
2004-06-16
Brief Title:
Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Key Dates - Follows AllAPIJSON File Order
Start Date:
2004-04
Start Date Type:
None
Primary Completion Date:
None
Primary Completion Date Type:
None
Completion Date:
None
Completion Date Type:
None
First Submit Date:
2004-06-16
First Submit QC Date:
June 17 2004
Study First Post Date:
2004-06-18
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2008-10-09
Last Update Post Date:
2008-10-13
Last Update Post Date Type:
ESTIMATED